Simultaneous Inhibition of PD-1 and Stimulation of CD40 Signaling Pathways by Anti-PD-L1/CD40L Bispecific Fusion Protein Synergistically Activate Target and Effector Cells

Bispecific antibodies (BsAbs) or fusion proteins (BsAbFPs) present a promising strategy for cancer immunotherapy. Numerous BsAbs targeting coinhibitory and costimulatory pathways have been developed for retargeting T cells and antigen presenting cells (APCs). It is challenging to assess the potency...

Descripción completa

Detalles Bibliográficos
Autores principales: Pandey, Madhu S., Wang, Chunlei, Umlauf, Scott, Lin, Shihua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8583728/
https://www.ncbi.nlm.nih.gov/pubmed/34768776
http://dx.doi.org/10.3390/ijms222111302

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8583728/
https://www.ncbi.nlm.nih.gov/pubmed/34768776
http://dx.doi.org/10.3390/ijms222111302

Ejemplares similares